RxDoctor Payments Data

Harry Claybrook, MD

Internal Medicine · Bristol, TNNPI 1801892765

Payments from drug & device makers

$9,262in general payments, 2019–2025

Across 619 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$990
  • GSK$766
  • Amgen$669
  • AstraZeneca$634
  • Takeda Pharmaceuticals U.S.A., Inc.$525
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$9,232100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,262 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$156,195
Medicare patients
416
Services billed
2,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$89,828
OzempicSemaglutide25$43,882
JardianceEmpagliflozin42$42,401
Humulin R U-500 KwikpenInsulin Regular, Human26$38,453
XareltoRivaroxaban41$37,463
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog37$36,578
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$33,900
FarxigaDapagliflozin Propanediol35$30,184
Repatha SureclickEvolocumab28$22,823
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$17,190
TrulicityDulaglutide12$13,001
MounjaroTirzepatide11$12,734
MyrbetriqMirabegron22$10,570
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$8,863
Breo ElliptaFluticasone/Vilanterol16$8,690

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$483$89,828102 claims
Novo NordiskOzempic$990$43,88225 claims
GSKTrelegy Ellipta, Breo Ellipta$766$42,59059 claims
Boehringer IngelheimJardiance$208$42,40142 claims
AstraZenecaFarxiga, Breztri Aerosphere$634$39,04747 claims
Johnson & JohnsonXarelto$211$37,46341 claims
Lilly USA, LLCTrulicity, Mounjaro$350$25,73523 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$525$6,43713 claims
AbbVieSynthroid$1,428$3,74748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Bristol

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →